📅 PUBMED DAILY TRIAGE — 2026-07-14 Window: 2026-07-13T09:00:00Z → 2026-07-14T09:00:00Z (CRDT) Topics scanned: 10 | Candidates reviewed: 120 PMIDs across 10 topics | Articles retained: 44 High priority: 11 | Standard: 33 | Low/archive: 0 | Unsolicited finds: 1 Run status: SUCCESS
🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic
Hematologic malignancies
- PMID 42441929 · Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated H... · 9/10 🟢 → Phase 3 ENHANCE trial: magrolimab plus azacitidine did not improve CR rate (21.3% vs 23.6%, p=0.52) or median OS (15.9 vs 18.6 months, p=0.13) versus azacitidine alone in treatment-naive higher-risk MDS, while grade ≥3 A...
CBC-based diagnostics and machine learning in hematology
- PMID 42443137 · Performance of the CellaVision advanced RBC application for schistocyte counting in the ... · 8/10 🟢 → CellaVision Advanced RBC Application (ARBCA) AI showed excellent overall agreement with expert schistocyte counts (no systematic bias, kappa=0.85) but underestimated schistocytes in MAHA cases (optimal cutoff ≥1.62% for ...
Early cancer detection
- PMID 42442380 · Switching to camizestrant at ESR1 mutation emergence before disease progression during f... · 9/10 🟠 → In SERENA-6, preemptive switching to camizestrant plus CDK4/6 inhibitor upon ctDNA-detected ESR1 mutation emergence before radiological progression significantly improved PFS (16.8 vs 9.2 months; HR 0.45, p<0.0001) and s...
AI/ML in clinical diagnostics and imaging
- PMID 42442328 · Serum metabolomics profiling in head and neck squamous cell carcinoma: a multicentre dia... · 8/10 🔴 → An 8-metabolite serum metabolomics model based on arginine metabolism alterations detected HNSCC with AUC 0.901 in multicenter external validation and AUC 0.927 in Stage I disease, with 91.1% sensitivity and 80.2% specif...
Precision oncology and genomic medicine
PMID 42442074 · Uptake of breast cancer risk-management strategies among unaffected BRCA 1/2 carriers: a... · 8/10 🟢 → In this systematic review of 32 international studies, RRM uptake among unaffected BRCA1/2 carriers ranged 0–81.6% with consistently higher uptake in North America and Norway versus Asian and Middle Eastern populations, ...
PMID 42443179 · A tumor profiling resource for ovarian cancer: insights into chemotherapy-driven heterog... · 8/10 🟢 → Comprehensive multimodal molecular profiling of blood, tumor tissue, and malignant ascites using 11 technologies in a 4-week turnaround altered hypothetical treatment recommendations for 76% of high-grade serous ovarian ...
Novel therapeutics: immunotherapy, CAR-T, targeted therapy
PMID 42442381 · Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid ... · 9/10 🟠 → In the first phase 3 RCT of dabrafenib plus trametinib in BRAF V600E-positive RAI-refractory differentiated thyroid cancer, the combination significantly improved PFS (12.8 vs 3.7 months; HR 0.38, p<0.0001) and overall r...
PMID 42443515 · An anti-PMEL antibody-drug conjugate with a G(q/1)(1) inhibitor payload in GNAQ/GNA11-mu... · 9/10 🟠 → DYP688, a first-in-class biology-matched ADC targeting PMEL and delivering a Gq/11 inhibitor payload, achieved 19.7% objective response and 71.2% tumor reduction rates with manageable toxicity (grade 3 TRAEs in 7.6%) and...
Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk
- PMID 42443144 · Safety Profile of Tirzepatide in Real-World Clinical Practice: A Pharmacovigilance Study... · 8/10 🟢 → Tirzepatide real-world safety analysis (123,145 FAERS reports) identified medication errors, injection-site reactions, and GI disorders as strongest signals; novel unlabeled signals including starvation ketoacidosis, eru...
Aging, longevity, and population health
No high-priority finds today (best candidate scored 7/10, PMID 42439614)
Rare diseases with high unmet need
PMID 42442367 · Landscape of parental postzygotic mutations across >11,000 rare disease trios. · 9/10 🟢 → A bioinformatic approach applied to >12,000 rare disease clinical WGS trios identified 1,015 high-confidence parental postzygotic mutations (PZMs)—including clinically relevant variants in DYNC1H1 and WT1 missed by routi...
PMID 42440435 · The impact of subtotal pancreatectomy on people with congenital hyperinsulinism and thei... · 8/10 🟡 → Among 34 children with diffuse congenital hyperinsulinism undergoing ≥75% pancreatectomy, only 9% had normal glucose at discharge; 44% developed diabetes, 41% pancreatic insufficiency, and 24% required ongoing hypoglycem...
🟢⚪ STANDARD (5-7) — Top by Topic
Hematologic malignancies
- 42442615 · Clinical outcomes of Epstein-Barr virus infection/reactivation following CA... · 7/10 · Treatment Innovation
- 42442416 · Feasibility and Safety of Venetoclax for Cytoreduction During Induction The... · 6/10 · Treatment Innovation
- 42443469 · Transplantation outcomes in Philadelphia-positive acute lymphoblastic leuke... · 6/10 · Treatment Innovation
- 42443016 · [Burkitt lymphoma: Definition, diagnostic approach, and current therapeutic... · 5/10 · Treatment Innovation
- 42443409 · PLK1 inhibition enhances Brentuximab vedotin efficacy in CD30-positive T-ce... · 5/10 · Drug Development
CBC-based diagnostics and machine learning in hematology
- 42438636 · Detecting Pseudothrombocytopenia in the Era of Artificial Intelligence: Int... · 5/10 · Diagnostics
Early cancer detection
- 42438137 · Highly Efficient Isolation and Rapid Detection of Pancreatic Cancer-Derived... · 7/10 · Early Detection
- 42440508 · Liquid biopsy in pediatric acute lymphoblastic leukemia. · 7/10 · Early Detection
- 42441700 · Profiling Epidermal Growth Factor Receptor DNA Mutations In Circulating Rar... · 6/10 · Diagnostics
- 42443324 · Fragmentation-Induced Coverage Biases in Cell-Free DNA Sequencing Affect th... · 6/10 · Early Detection
AI/ML in clinical diagnostics and imaging
- 42442345 · Multimodal Machine Learning Model Predicting Postoperative Delirium Based o... · 7/10 · Diagnostics
- 42442924 · fAI-BRO: a multimodal AI decision-support system to address diagnostic dela... · 7/10 · Diagnostics
- 42443009 · Machine Learning for Predicting Ki-67 Expression in Renal Tumors: A Systema... · 7/10 · Diagnostics
- 42443230 · Open dataset and deep learning model for intelligent diagnosis of neonatal ... · 7/10 · Diagnostics
Precision oncology and genomic medicine
- 42442611 · High-throughput acoustic FFPE proteomics reveals ATP5IF1-associated mitocho... · 7/10 · Genomics/Precision Medicine
- 42443519 · Multi-omics fusion with machine learning enables robust prediction of treat... · 7/10 · Genomics/Precision Medicine
- 42443809 · Distinct genomic landscape of colorectal signet ring cell carcinoma reveals... · 6/10 · Genomics/Precision Medicine
Novel therapeutics: immunotherapy, CAR-T, targeted therapy
- 42443174 · Transcriptomic analysis of tissue-resident memory T cells of the fallopian ... · 7/10 · Genomics/Precision Medicine
- 42442732 · Neutrophil-to-Lymphocyte Ratio and Extrahepatic Spread Predict Response and... · 6/10 · Treatment Innovation
- 42443037 · Neural checkpoint therapy in lung cancer. · 6/10 · Treatment Innovation
- 42443802 · NLR-based nomogram predicts survival in hepatocellular carcinoma treated wi... · 6/10 · Diagnostics
Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk
- 42442963 · The long-term cardiovascular benefits of metabolic and bariatric surgery ve... · 7/10 · Treatment Innovation
- 42443140 · Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability o... · 7/10 · Drug Development
- 42443272 · The association of SPISE with cardiometabolic multimorbidity and stroke in ... · 7/10 · Prevention
- 42443583 · Differential Biventricular Strain Recovery With Selective Fibrosis Biomarke... · 7/10 · Prevention
- 42443652 · Automated Deep Learning Segmentation and Quantification of Epicardial Adipo... · 7/10 · Diagnostics
Aging, longevity, and population health
- 42439047 · The social environment and cognitive aging over the life course: laying out... · 7/10 · Public Health
- 42439614 · Inflammatory Signatures in MDS: The Missing Link Between Genetics, Microenv... · 7/10 · Genomics/Precision Medicine
- 42439654 · Emerging New Pathways in Malignant Neoplasms and Neurodegenerative Disorder... · 6/10 · Treatment Innovation
Rare diseases with high unmet need
- 42440806 · The Chronic Angioedema Registry: what the first 2 years since the implement... · 7/10 · Public Health
- 42443585 · Genetic architecture of lung cancer revealed by common and rare variant ana... · 7/10 · Genomics/Precision Medicine
- 42443618 · Artificial Intelligence in Clinical Genetics: Current Applications and Chal... · 7/10 · Diagnostics
💡 UNSOLICITED FINDS
- PMID 42442095 · Risk of bias and clinical benefit of phase III trials supporting FDA-approved anticancer... · 7/10 → Cross-sectional analysis of pivotal phase 3 trials supporting FDA anticancer drug approvals 2018–2025 identified variable risk of bias and inconsistent clinical benefit magnitude, with a substantial p...
📊 TODAY'S BREAKDOWN
By research category:
- Treatment Innovation: 12
- Diagnostics: 10
- Genomics/Precision Medicine: 8
- Early Detection: 4
- Prevention: 3
- Drug Development: 3
- Other: 2
- Public Health: 2
By evidence maturity:
- Exploratory: 25
- Validated: 16
- Potentially Practice-Changing: 3
By watchlist topic (candidates reviewed → retained → highest score):
- Hematologic malignancies: reviewed=15 | retained HIGH=0 STD=5 | best=7/10
- CBC-based diagnostics and machine learning in hematolog: reviewed=2 | retained HIGH=1 STD=1 | best=8/10
- Early cancer detection: reviewed=13 | retained HIGH=1 STD=4 | best=9/10
- AI/ML in clinical diagnostics and imaging: reviewed=15 | retained HIGH=1 STD=4 | best=8/10
- Precision oncology and genomic medicine: reviewed=15 | retained HIGH=2 STD=3 | best=8/10
- Novel therapeutics: immunotherapy, CAR-T, targeted ther: reviewed=15 | retained HIGH=1 STD=7 | best=9/10
- Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic: reviewed=15 | retained HIGH=1 STD=5 | best=8/10
- Aging, longevity, and population health: reviewed=15 | retained HIGH=0 STD=3 | best=7/10
- Rare diseases with high unmet need: reviewed=12 | retained HIGH=2 STD=3 | best=9/10
By source type: peer_reviewed=44 | preprint=0
Topics with zero 8+ articles this run: Hematologic malignancies, Aging, longevity, and population health
🔧 RUN NOTES
- Window: CRDT 2026-07-13T09:00:00Z → 2026-07-14T09:00:00Z (last 24h; no prior checkpoint)
- Window expansion: Not triggered. T2 (CBC/ML) returned only 2 raw candidates but both were relevant; <5 threshold narrowly not met.
- Coverage: All 120 candidate PMIDs successfully fetched via efetch (rettype=medline). coverage_complete=true for all 10 topics + SENTINEL.
- T2 (CBC/ML sparse): Only 2 candidates (raw_count=2). Both reviewed and scored: HIGH=1, STANDARD=1. No fallback query needed.
- Sentinel overlap: 4 of 10 SENTINEL candidates already captured by watchlist topics (42442380, 42443515, 42441929, 42442381). Only 1 novel unsolicited find: PMID 42442095 (FDA trial quality meta-research).
- T1 noise: 8 of 15 T1 (Hematologic malignancies) candidates were off-topic (tubo-ovarian abscess, Parkinson's disease, peripheral artery disease, erratum). Query refinement with tighter exclusions recommended for next run.
- Negative trial note: PMID 42441929 (Magrolimab ENHANCE Phase 3 MDS) scored HIGH 9/10 as a definitively negative phase 3 RCT; CR and OS primary endpoints not met; more severe AEs in magrolimab arm. flag=NEAR_TERM_IMPLEMENTABLE (prevents adoption of a more toxic non-superior regimen).
- Aging/longevity: humans[MeSH] filter applied per v1.3 guidance; raw_count=17, all human studies, no non-human noise observed this run.
- Errors: None. API rate limits not exceeded (10 req/sec with key).
- Attempt: 1 of 3